PE20231573A1 - Anticuerpos biespecificos cd47-cd38 - Google Patents
Anticuerpos biespecificos cd47-cd38Info
- Publication number
- PE20231573A1 PE20231573A1 PE2023001174A PE2023001174A PE20231573A1 PE 20231573 A1 PE20231573 A1 PE 20231573A1 PE 2023001174 A PE2023001174 A PE 2023001174A PE 2023001174 A PE2023001174 A PE 2023001174A PE 20231573 A1 PE20231573 A1 PE 20231573A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- binds
- human
- bispecific antibodies
- binding portion
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Referida a un anticuerpo biespecifico que comprende al menos dos porciones de union, al menos una de las cuales se une a la CD38 humana y al menos una de las cuales se une a la CD47 humana, donde dicha porcion de union que se une a la CD38 humana comprende un conjunto de CDRs seleccionado del grupo que comprende: SEQ ID NO: 103, SEQ ID NO: 163, SEQ ID NO: 223; SEQ ID NO: 117, SEQ ID NO: 177, SEQ ID NO: 237; SEQ ID NO: 121; SEQ ID NO: 181, SEQ ID NO: 241 y la porcion de union que se une a la CD47 humana comprende un conjunto de CDRs que comprende: SEQ ID NO: 75, SEQ ID NO: 135, SEQ ID NO: 195. Dichos anticuerpos son utiles para tratar enfermedades autoinmunitarias y proliferativas y en particular tipos de cancer tales como neoplasias malignas hematologicas y tumores solidos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20197033 | 2020-09-18 | ||
| PCT/EP2021/075687 WO2022058539A1 (en) | 2020-09-18 | 2021-09-17 | Cd47-cd38 bispecific antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20231573A1 true PE20231573A1 (es) | 2023-10-04 |
Family
ID=72603323
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023001174A PE20231573A1 (es) | 2020-09-18 | 2021-09-17 | Anticuerpos biespecificos cd47-cd38 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US12338292B2 (es) |
| EP (1) | EP4214231A1 (es) |
| JP (1) | JP2023542907A (es) |
| KR (1) | KR20230088370A (es) |
| CN (1) | CN116648463A (es) |
| AR (1) | AR123548A1 (es) |
| AU (1) | AU2021344635A1 (es) |
| CA (1) | CA3192465A1 (es) |
| CL (1) | CL2023000786A1 (es) |
| CO (1) | CO2023004698A2 (es) |
| IL (1) | IL301330A (es) |
| MX (1) | MX2023003192A (es) |
| PE (1) | PE20231573A1 (es) |
| TW (1) | TW202227497A (es) |
| WO (1) | WO2022058539A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12338292B2 (en) | 2020-09-18 | 2025-06-24 | IGI Therapeutics SA | CD47-CD38 bispecific antibodies |
| US20240228650A9 (en) * | 2022-05-06 | 2024-07-11 | Ichnos Sciences SA | CD3/BCMA/CD38 Trispecific Antibodies |
| KR20250008774A (ko) * | 2022-05-11 | 2025-01-15 | 셀진 코포레이션 | T 세포 요법 및 그의 생산과 관련된 방법 및 용도 |
| WO2024121311A1 (en) * | 2022-12-07 | 2024-06-13 | Ichnos Sciences SA | Cd47/cd38 bispecific antibodies and methods of use to treat leukemia |
| WO2024126833A1 (en) * | 2022-12-16 | 2024-06-20 | Ichnos Sciences SA | Cd47-il1rap bispecific antibodies |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| ES2532910T3 (es) | 1998-04-02 | 2015-04-01 | Genentech, Inc. | Variantes de anticuerpos y fragmentos de los mismos |
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| RU2015102845A (ru) | 2010-02-23 | 2015-06-10 | Санофи | АНТИТЕЛА К ИНТЕГРИНУ α2 И ИХ ПРИМЕНЕНИЯ |
| KR20200052383A (ko) | 2011-03-25 | 2020-05-14 | 아이크노스 사이언스 에스. 아. | 헤테로 이량체 면역글로불린 |
| TWI622597B (zh) | 2011-03-28 | 2018-05-01 | 賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| CN109476732B (zh) | 2016-04-13 | 2024-03-22 | 赛诺菲 | 三特异性和/或三价结合蛋白 |
| CN111303293B (zh) | 2018-11-14 | 2022-08-30 | 杭州尚健生物技术有限公司 | 一种融合蛋白及其用途 |
| US12338292B2 (en) | 2020-09-18 | 2025-06-24 | IGI Therapeutics SA | CD47-CD38 bispecific antibodies |
-
2021
- 2021-09-17 US US17/478,706 patent/US12338292B2/en active Active
- 2021-09-17 EP EP21782659.3A patent/EP4214231A1/en active Pending
- 2021-09-17 KR KR1020237013184A patent/KR20230088370A/ko active Pending
- 2021-09-17 IL IL301330A patent/IL301330A/en unknown
- 2021-09-17 JP JP2023517964A patent/JP2023542907A/ja active Pending
- 2021-09-17 AU AU2021344635A patent/AU2021344635A1/en active Pending
- 2021-09-17 CN CN202180076954.9A patent/CN116648463A/zh active Pending
- 2021-09-17 MX MX2023003192A patent/MX2023003192A/es unknown
- 2021-09-17 CA CA3192465A patent/CA3192465A1/en active Pending
- 2021-09-17 AR ARP210102596A patent/AR123548A1/es unknown
- 2021-09-17 WO PCT/EP2021/075687 patent/WO2022058539A1/en active Application Filing
- 2021-09-17 PE PE2023001174A patent/PE20231573A1/es unknown
- 2021-09-18 TW TW110135023A patent/TW202227497A/zh unknown
-
2023
- 2023-03-17 CL CL2023000786A patent/CL2023000786A1/es unknown
- 2023-04-17 CO CONC2023/0004698A patent/CO2023004698A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4214231A1 (en) | 2023-07-26 |
| AR123548A1 (es) | 2022-12-14 |
| MX2023003192A (es) | 2023-06-09 |
| CO2023004698A2 (es) | 2023-07-21 |
| TW202227497A (zh) | 2022-07-16 |
| CA3192465A1 (en) | 2022-03-24 |
| IL301330A (en) | 2023-05-01 |
| US12338292B2 (en) | 2025-06-24 |
| CN116648463A (zh) | 2023-08-25 |
| US20220089767A1 (en) | 2022-03-24 |
| AU2021344635A9 (en) | 2024-02-08 |
| CL2023000786A1 (es) | 2023-09-15 |
| WO2022058539A1 (en) | 2022-03-24 |
| AU2021344635A1 (en) | 2023-04-27 |
| JP2023542907A (ja) | 2023-10-12 |
| KR20230088370A (ko) | 2023-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20231573A1 (es) | Anticuerpos biespecificos cd47-cd38 | |
| EA201990781A1 (ru) | Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение | |
| CR20120454A (es) | Proteínas terapéuticas de unión a dll4 | |
| EA201891428A1 (ru) | Комбинация антител к pd-1 и биспецифических антител к cd20/cd3 для лечения злокачественной опухоли | |
| BR112023002895A2 (pt) | Anticorpos anti-ror1 e proteínas de ligação biespecíficas relacionadas | |
| CO2018004094A2 (es) | Polipéptidos de unión a cd3 | |
| EA201792522A1 (ru) | Лечение злокачественной опухоли с помощью комбинированной блокады сигнальных путей pd-1 и cxcr4 | |
| EA201992526A1 (ru) | Стабильные составы анти-ctla4 антител, отдельно и в комбинации с антителами против рецептора 1 программируемой смерти (pd-1), и способы их применения | |
| NZ735052A (en) | Therapeutic antibodies and their uses | |
| MY160662A (en) | T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2 | |
| DOP2012000052A (es) | Proteínas terapéuticas de unión a dll4 | |
| BR112017025080A2 (pt) | composto conjugado de fármaco com anticorpo anti-cd123, composição conjugada de fármaco com anticorpo, método de tratamento de um paciente que tem um câncer que expressa cd123, composição farmacêutica, e, anticorpo intacto ou fragmento de ligação de antígeno | |
| EA201691858A1 (ru) | Композиции антител для лечения опухолей | |
| PE20220142A1 (es) | Anticuerpos de cadena pesada que se unen al psma | |
| EA201691487A1 (ru) | Антитела человека к pd-l1 | |
| MX2022006230A (es) | Anticuerpos contra cd3 y bcma, y proteinas de union biespecificas hechas a partir de estos. | |
| MX2020008289A (es) | Moleculas biespecificas de union al antigeno y metodos de uso. | |
| PH12022551098A1 (en) | Treatment of cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins | |
| MX2022000779A (es) | Anticuerpo monoclonal anti-vegf humanizado. | |
| MX2023004089A (es) | Métodos para el tratamiento del cáncer con conjugados de fármaco y anticuerpos (adc) que se unen a las proteínas 191p4d12. | |
| CR20240462A (es) | Anticuerpos biespecíficos que comprenden un dominio de unión a nrp1 y métodos de uso de los mismos | |
| MX2023013392A (es) | Anticuerpos para tratar alfa-sinucleinopatias. | |
| BR112021020873A2 (pt) | Métodos para tratamento de câncer renal com um anticorpo anti-psma/cd3 | |
| EA202091978A1 (ru) | Биспецифические связывающие агенты и варианты их применения | |
| AR110819A1 (es) | Anticuerpos anti-fgfr (receptor del factor de crecimiento de fibroblastos) y métodos de uso |